title: Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
authors.forename: K
authors.initials: K
authors.lastname: Immonen
authors.forename: M
authors.initials: M
authors.lastname: Kauppi
authors.forename: M
authors.initials: M
authors.lastname: Hakala
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000686:Amyloidosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D001706:Biopsy; D005260:Female; D006801:Humans; D008297:Male; D000685:Serum Amyloid A Protein / Q000378:metabolism; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D050507:Subcutaneous Fat, Abdominal / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000685:Serum Amyloid A Protein; D000068879:Adalimumab; C502936:tocilizumab